{
    "name": "omidenepag isopropyl ophthalmic",
    "comment": "Rx",
    "other_names": [
        "Omlonti"
    ],
    "classes": [
        "Antiglaucoma",
        "Prostaglandin Agonists"
    ],
    "source": "https://reference.medscape.com/drug/omlonti-omidenepag-isopropyl-ophthalmic-4000199",
    "pregnancy": {
        "common": [
            "Data are unavailable on use in pregnant females"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "SC administration of omidenepag isopropyl to pregnant rabbits throughout organogenesis produced fetal skeletal anomalies at a dose of 24x the clinical dose, based on estimated peak plasma concentration",
                    "Omidenepag isopropyl was not teratogenic in rats when administered SC at 1 mg/kg/day, 2,452x the clinical dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on drug presence in human milk, effects on breastfed infants, or effects on milk production",
            "Systemic exposure to omidenepag following topical ocular administration is low, and it is unknown whether measurable levels of omidenepag would be present in maternal milk following topical ocular administration"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "May gradually change eyelashes and vellus hair in treated eye; changes include increased length, thickness, and number of lashes or hairs; eyelash changes are usually reversible upon discontinuing treatment",
                "Ocular inflammation reported; use with caution in patients with active ocular inflammation, including iritis/uveitis",
                "Macular edema, including cystoid macular edema, reported; caution in aphakic patients, in pseudophakic patients, or in patients with known risk factors for macular edema",
                "Advise patients to avoid touching bottle tip to eye or any surface, as this may contaminate solution",
                "Advise patients not to touch tip to their eye to avoid the potential for injury to eye"
            ],
            "specific": [
                {
                    "type": "Pigmentation changes",
                    "description": [
                        "Pigmentation changes are expected to occur and increase if omidenepag isopropyl ophthalmic solution is administered",
                        "Pigmentation change is due to increased melanin content in melanocytes rather than increased number of melanocytes",
                        "Iris color change may not be noticeable for several months to years",
                        "Long term effects of pigmentation are not known",
                        "The brown pigmentation around the pupil may spread concentrically towards the periphery ofthe iris and the entire iris or parts of the iris become more brownish",
                        "Neither nevi nor freckles of the iris appear to be affected by treatment; while treatment can be continued in patients who develop noticeably increased iris pigmentation, examine regularly",
                        "After discontinuing, iris pigmentation is likely to be permanent, while pigmentation of periorbital tissue and eyelash changes are reversible in most patients",
                        "Inform patient receiving prostaglandin analogs of possible increased pigmentation, including permanent changes"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Conjunctival hyperemia",
            "percent": "9"
        },
        {
            "name": "Photophobia",
            "percent": "5"
        },
        {
            "name": "Vision blurred",
            "percent": "4"
        },
        {
            "name": "Dry eye",
            "percent": "3"
        },
        {
            "name": "Instillation site pain",
            "percent": "3"
        },
        {
            "name": "Eye pain",
            "percent": "2"
        },
        {
            "name": "Ocular hyperemia",
            "percent": "2"
        },
        {
            "name": "Punctate keratitis",
            "percent": "2"
        },
        {
            "name": "Headache",
            "percent": "2"
        },
        {
            "name": "Eye irritation",
            "percent": "1"
        },
        {
            "name": "Visual impairment",
            "percent": "1"
        }
    ]
}